↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Rigacci L) "

Search: WFRF:(Rigacci L)

Result 1-3 of 3

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Moreno, C, et al. (author) Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia 2015 In: Haematologica. - : Ferrata Storti Foundation (Haematologica). - 1592-8721 .- 0390-6078. ; 100:4, s. 514-519 Journal article (peer-reviewed)
2.	Messori, A, et al. (author) Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP 2001 In: British Journal of Cancer. - : Springer Science and Business Media LLC. - 1532-1827. ; 84:3, s. 303-307 Journal article (peer-reviewed)abstract In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival up to 9 years after randomization was compared between the two treatment options. The results of our meta-analysis showed that, in comparison with CHOP, third generation chemotherapy did not prolong survival at levels of statistical significance (chi-square by log-rank test = 1.44, P = 0.23). The relative death risk for third generation regimens vs. CHOP was 0.92 (95%CI: 0.80 to 1.06;P = 0.26). We conclude that, on the basis of our meta-analysis, third generation regimens do not confer any survival benefit to patients with intermediate or high grade NHL as compared with CHOP.
3.	Schmidt-Hieber, M, et al. (author) Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT 2020 In: Journal of neurology. - : Springer Science and Business Media LLC. - 1432-1459 .- 0340-5354. ; 268267:62, s. 430-439 Journal article (peer-reviewed)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-3 of 3

Refine your search

Type of publication: journal article (3)

Type of content: peer-reviewed (3)

Author/Editor: Isaksson, C (1); Jerkeman, Mats (1); Farina, L. (1); Ljungman, P (1); Kimby, E (1); Pospisilova, S (1); show more...; Ghia, P (1); Stamatopoulos, K (1); Montillo, M. (1); Stilgenbauer, S. (1); Moreno, C (1); Schuh, A (1); Wang, JF (1); Saccardi, R (1); Faraci, M (1); Dupuis, J (1); Hillmen, P. (1); Byrne, J. (1); Maertens, J (1); Faber, E (1); Montserrat, E (1); Rovira, M (1); Robin, C. (1); Longo, G. (1); Panayiotidis, P (1); Tridello, G (1); Mikulska, M (1); Shaw, PJ (1); Styczynski, J (1); Engelhard, D (1); Cesaro, S (1); Martino, R (1); Geisler, C. (1); Doubek, M. (1); Stavroyianni, N. (1); Einsele, H (1); Dimou, M (1); Trneny, M (1); Leblond, V (1); Cymbalista, F (1); Schafer-Eckart, K (1); Knelange, N (1); Laurenti, L (1); Marasca, R (1); Norin, S (1); Rubio, M (1); Paolini, R (1); Bloor, A (1); Jaeger, U (1); Bradley, C. (1); show less...

University: Karolinska Institutet (2); Lund University (1)

Language: English (3)

Research subject (UKÄ/SCB): Medical and Health Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view